{"id":"W4399881235","doi":"10.1200/jco.2024.42.16_suppl.4100","title":"Pembrolizumab (pembro) in patients (pts) with sorafenib-treated (cohort 1) and treatment (tx)-naive (cohort 2) advanced hepatocellular carcinoma (aHCC) after additional follow-up in the phase 2 KEYNOTE-224 study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Sorafenib; Pembrolizumab; Cohort; Internal medicine; Oncology; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005616096,0.0003039501,0.0004266445,0.0002253467,0.0002997638,0.0005720734,0.000267812,0.0004115033,0.00199712],"category_scores_gemma":[0.0006007616,0.000255801,0.0005338159,0.0003020033,0.0002255043,0.000565901,0.0003527058,0.0007297418,0.0002955066],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006151693,"about_ca_system_score_gemma":0.0005245551,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009017839,"about_ca_topic_score_gemma":0.00231561,"domain_scores_codex":[0.9997489,0.00006037355,0.00001894661,0.00009793605,0.00002907715,0.00004477908],"domain_scores_gemma":[0.99968,0.00003189479,0.0001264186,0.00002934485,0.00001906653,0.0001132552],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2767357,0.007256909,0.6247759,0.000615998,0.00228124,0.001283839,0.0003760209,0.001499129,0.01710039,0.0003301438,0.00760251,0.06014218],"study_design_scores_gemma":[0.0332089,0.07151406,0.8765125,0.0001109318,0.00132597,0.002423095,0.0003067013,0.001726999,0.00269645,0.0003080587,0.00982115,0.00004521651],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.996852,0.0005958878,0.0001187615,0.00006796033,0.00001833955,0.0002289356,0.001523307,0.0000100958,0.0005848278],"genre_scores_gemma":[0.9956968,0.0002268616,0.0001528197,0.0001349106,0.00003217796,0.0001697858,0.003086708,0.00000225625,0.0004976425],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00199712,"threshold_uncertainty_score":0.006681025,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08591963113597074,"score_gpt":0.3712702723637485,"score_spread":0.2853506412277778,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}